One study illustrated that the combination of FMT with anti-VEGF and anti-PD-1 therapies effectively enhanced treatment for proficient mismatch repair (pMMR) and microsatellite stable (MSS) CRC (Cheng et al. 2023). This evidence concerns the gene VEGFA and colorectal carcinoma.